



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

15 October 2020
EMA/CHMP/551424/2020
Committee for Medicinal Products for Human Use (CHMP)

Summary of opinion¹ (post authorisation)

Edistride

dapagliflozin

On 15 October 2020, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Edistride. The marketing authorisation holder for this medicinal products is AstraZeneca AB.

The CHMP adopted a new indication as follows:

Heart failure

Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

For information, the full indications for Edistride will be as follows²:

Type 2 diabetes mellitus

Edistride is indicated in adults for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise

- as monotherapy when metformin is considered inappropriate due to intolerance.
- in addition to other medicinal products for the treatment of type 2 diabetes.

For study results with respect to combination of therapies, effects on glycaemic control and cardiovascular events, and the populations studied, see sections 4.4, 4.5 and 5.1.

Heart failure

Edistride is indicated in adults for the treatment of symptomatic chronic heart failure with reduced ejection fraction.

Detailed recommendations for the use of this product will be described in the updated summary of product

¹ Summaries of positive opinion are published without prejudice to the Commission decision, which will normally be issued 67 days from adoption of the opinion

² **New text in bold**



characteristics (SmPC), which will be published in the revised European public assessment report (EPAR), and will be available in all official European Union languages after a decision on this change to the marketing authorisation has been granted by the European Commission.